DRUG · Unmapped registry intervention
LY3209590
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
NCT03736785
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Insulin Degludec
Normalized identity: insulin degludecView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
LY3209590DRUG
Insulin DegludecDRUG · verified · RxNorm: insulin degludec
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
Las VegasNevada, United States2Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1San AntonioTexas, United States1BirminghamAlabama, United States1AustinTexas, United States1CharlotteNorth Carolina, United States1Little RockArkansas, United States1HonoluluHawaii, United States1FresnoCalifornia, United States1West Palm BeachFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03736785 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.